Search Results 911-920 of 13900 for Assay
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study ...
Likewise, the B cell assays under development will predict patients at risk of developing lung fibrosis and also identify patients that will benefit from B cell ...
The purpose of this study is to recruit 2000 incident cases of primary breast cancer in order to perform laboratory assays to measure frequencies of genetic ...
Serum free light chain (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/L) and an abnormal serum FLC ratio (< 0.26 or > 1.65). Subject has confirmed ...
... assays performed in clinical laboratory improvement amendments (CLIA)-approved laboratories ... assay. Exclusion Criteria: Definitive clinical or radiologic ...
... assay: involved SFLCs >/= 10 mg/dL (>/= 100 mg/L) and an abnormal SFLC ratio (<0.26 or >1.65). Female participants of childbearing potential must have a ...
The purpose of this study is to validate an internally developed assay for the detection of BRAF V600E mutations in cfDNA from the peripheral blood of patients ...
Lucien-Matteoni's lab uses advanced proteomic methodologies, functional assays and animal models to characterize the identity and function of the cancer ...
... assays into clinical tests. Cancer genomics. Dr. Hart works toward integrated next-generation sequencing data analysis of multiple genomic features, such as ...
... assay. Exclusion Criteria: Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.